On Tuesday, PTC Therapeutics Inc (NASDAQ:PTCT) revealed data from the global Phase 2 placebo-controlled CardinALS study of Utreloxastat in amyotrophic lateral sclerosis patients.
The study did not meet its primary endpoint of slowing disease progression on the composite ALSFRS-R and mortality analysis.
Also Read: FDA Grants Conditional Approval For PTC Therapeutics’ Gene Therapy As First Ever With Direct Administration In Brain
While modest numerical benefit was recorded on the primary endpoint, and a favorable clinical effect was correlated with lowering plasma neurofilament light chain (NfL), a biomarker of neuronal damage, statistical significance was not achieved (p= 0.52). In addition, significance was not achieved on the secondary efficacy endpoints.
Amyotrophic lateral sclerosis (ALS), sometimes referred to as motor neuron disease or Lou Gehrig’s disease, is a rare neurodegenerative disease that affects motor neurons in the brain and spinal cord.
Utreloxastat was demonstrated to be safe and well-tolerated in the CardinALS trial. However, further development is not planned due to the lack of efficacy and biomarker signal.
William Blair notes that while the CardinALS trial results were disappointing, the program was not a major factor in its investment thesis. As a result, ending the program does not affect the firm’s Outperform rating on the stock.
The analyst highlights the potential approval and launch of sepiapterin as a key growth driver over the next year, particularly in treating Phenylketonuria (PKU). William Blair believes the market is undervaluing this opportunity, with a PDUFA decision expected in July.
The analyst also points to growing investor interest in the company’s Huntington’s disease program. Given the strong commercial prospects of this small-molecule therapy, positive discussions with regulators about an accelerated approval pathway for PTC-518 could significantly boost the stock. A Type C meeting with the FDA is planned for the fourth quarter to discuss the regulatory pathway.
Additionally, the company aims to file a U.S. marketing application for vatiquinone in Friedreich’s ataxia (FA) by late 2024. William Blair expects approval based on the drug’s clinical data and the FDA’s recent neurology approvals, especially as no treatments exist for pediatric FA patients.
On Wednesday, PTC Therapeutics agreed to sell its Rare Pediatric Disease Priority Review Voucher for $150 million.
PTC was granted the voucher along with the FDA approval of Kebilidi (eladocagene exuparvovec-tneq) for children and adults with AADC deficiency.
Price Action: PTCT stock is down 1.98% at $45.10 during the premarket session at last check Wednesday.
Read Next:
Illustration of Phrama lab worker created with MidJourney.
Date | Firm | Action | From | To |
---|---|---|---|---|
Feb 2022 | JP Morgan | Maintains | Overweight | |
Feb 2022 | Barclays | Maintains | Equal-Weight | |
Oct 2021 | Raymond James | Maintains | Outperform |
View More Analyst Ratings for PTCT
View the Latest Analyst Ratings
Up Next: Transform your trading with Benzinga Edge's one-of-a-kind market trade ideas and tools. Click now to access unique insights that can set you ahead in today's competitive market.
Get the latest stock analysis from Benzinga?
This article PTC Therapeutics Ends Utreloxastat Development After Rare Neurodegenerative Disease Trial Misses Goal, Analyst Maintains Outperform With Focus On Sepiapterin, Huntington's Programs originally appeared on Benzinga.com
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
免责声明:投资有风险,本文并非投资建议,以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请,作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考,不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证,投资者应自行研究并在投资前寻求专业建议。